Fri, May 31, 8:00 PM (143 days ago)
BioNexus Gene Lab Corp. has filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2023. This amendment addresses a specific issue raised by the SEC regarding the Company's disclosure controls and procedures. The original filing inaccurately described these controls as "capable," which is non-compliant with Item 307 of Regulation S-K. The amendment clarifies that the Company's disclosure controls and procedures were not effective for the period in question. There were no changes to the financial statements or other reported information from the original filing. No material changes to internal controls over financial reporting occurred during the period. This amendment should be read in conjunction with the original filing for a comprehensive understanding.